interferon gamma
Recently Published Documents


TOTAL DOCUMENTS

5691
(FIVE YEARS 738)

H-INDEX

144
(FIVE YEARS 8)

Cytokine ◽  
2022 ◽  
Vol 150 ◽  
pp. 155777
Author(s):  
Hailing Zhang ◽  
Shasha Zhang ◽  
Sining Fan ◽  
Lei Zhang ◽  
Bo Hu ◽  
...  

ADMET & DMPK ◽  
2022 ◽  
Author(s):  
Svetlana A. Berns ◽  
Julia A. Isakova ◽  
Polina Pekhtereva

Tuberculosis is one of the critical health problems worldwide. The search for ways to improve the results of tuberculosis treatment and overcome drug resistance lies in understanding the pathogenesis of the development of the infectious process. The interferon system, particularly the role of interferon-gamma, has been identified as the main link in the immune response in tuberculosis. The clinical efficacy of interferon-gamma has been studied and evaluated in clinical trials since the end of the last century. There was obtained evidence of the clinical efficacy of interferon-gamma as part of complex therapy. Recent experimental data make it possible to consider interferon-gamma as a promising therapeutic option for the treatment of multidrug-resistant tuberculosis as part of complex therapy worthy of further studies.  


Author(s):  
Mahmoud F. Dondeti ◽  
Mohamed S. Abdelkhalek ◽  
Hosam M El-Din Elezawy ◽  
Walaa F. Alsanie ◽  
Bassem M. Raafat ◽  
...  

2022 ◽  
Vol 12 (2) ◽  
pp. 761
Author(s):  
Mikhail Burlakovskiy ◽  
Natalia Saveleva ◽  
Andrey M. Rumyantsev ◽  
Vladislav V. Yemelyanov ◽  
Marina V. Padkina ◽  
...  

Many of the most modern drugs are of a protein nature and are synthesized by transgenic producer organisms. Bacteria, yeast, or animal cell cultures are commonly used, but plants have a number of advantages—minimal biomass unit cost, animal safety (plants are not attacked by mammalian pathogens), the agricultural scale of production, and the ability to produce complex proteins. A disadvantage of plants may be an unstable level of transgene expression, which depends on the transgene structure and its insertion site. We analyzed the structure of T-DNA inserts in transgenic tobacco plants (Nicotiana tabacum L.) belonging to two lines obtained using the same genetic construct but demonstrating different biological activities of the recombinant protein (bovine interferon-gamma). We found that, in one case, T-DNA was integrated into genomic DNA in the region of centromeric repeats, and in the other, into a transcriptionally active region of the genome. It was also found that in one case, the insert has a clustered structure and consists of three copies. Thus, the structure of T-DNA inserts in both lines is not optimal (the optimal structure includes a single copy of the insert located in the active region of the genome). It is desirable to carry out such studies at the early stages of transgenic plants selection.


Author(s):  
Pablo Barreiro ◽  
Juan Carlos Sanz ◽  
Jesús San Román ◽  
Marta Pérez-Abeledo ◽  
Mar Carretero ◽  
...  

Background: Assessment of T-cell responses to SARS-CoV-2 antigens may be of value to determine long-lasting protection to breakthrough infections or reinfections. Interferon-gamma release assay is a validated method to test cellular immunity in mycobacterial infections and has been proposed for patients with SARS-CoV-2 infection or vaccination. Methods: Quantitative IgG to spike and qualitative IgG to nucleocapsid antigens were determined by chemiluminescence microparticle immunoassay using the Architect® platform (Abbott®), and interferon-gamma release assay against two Qiagen® proprietary mixes of SARS-CoV-2 spike protein (antigen-1 and antigen-2) were performed for a selected group of subjects. Results: A total of 121 subjects in a cloistered institution after a COVID-19 outbreak were studied. IgG-spike levels and interferon-gamma concentration were highest among subjects after two doses of vaccine, followed by patients with a longer history of past COVID-19 and no vaccination. Best cut-off for interferon-gamma assay was 25 IU/μL for all subgroups of individuals and the two sets of SARS-CoV-2 antigens studied. Conclusions: Testing T-cell response may be of clinical utility to determine immunity after exposure to SARS-CoV-2 antigens, with the interferon-gamma concentration of 25 IU/μL as the best cut-off either after infection or vaccination.


2022 ◽  
Author(s):  
Irina A. Rakityanskaya ◽  
Tatiana S. Ryabova

Infection of Epstein-Barr virus (EBV) is about 90% among people over the age of 40. The EBV causes a chronic infection that is characterized by chronic or recurrent symptoms and persists for a long time. Recombinant interferon-gamma (IFN-γ) has high clinical and antiviral efficacy in the treatment of herpesvirus infections. 110 patients with chronic EBV infection were examined. The patients were divided into three groups for different treatment regimens: Group 1—IFN-γ therapy (15 injections of Ingaron i/m, 500,000 IU every other day); Group 2—valaciclovir (Valtrex 500 mg × 2 times/day, orally for 2 months); Group 3—valganciclovir (Valcyte 450 mg × 2 times/day, orally for 2 months) and IFN-γ (10–20 injections of Ingaron i/m, 500,000 IU every other day). The best results were obtained in group 3–73.07% negative PCR. In this group, the combination of valganciclovir + IFN-γ was different. We showed that the efficacy of therapy in patients with chronic EBV is determined by the duration of INF-γ administration. We also determined spontaneous and induced production of IFN-α and -γ cytokines in serum and in lymphocyte culture. We demonstrated that in patients with an initially low level of induced IFN-γ, the production of this cytokine significantly increased in three months after the end of therapy.


JBMR Plus ◽  
2022 ◽  
Author(s):  
Andrew Nguyen ◽  
Weston P. Miller ◽  
Ashish Gupta ◽  
Troy C. Lund ◽  
Daniel Schiferl ◽  
...  

2022 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Fanfan Xing ◽  
Derek L. L. Hung ◽  
Simon K. F. Lo ◽  
Shuang Chen ◽  
Susanna K. P. Lau ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document